Cover Image
Market Research Report

Hematological Malignancies: Multiple Myeloma (MM) - Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

Published by MP Advisors Product code 323219
Published Content info 82 Pages
Delivery time: 1-2 business days
Back to Top
Hematological Malignancies: Multiple Myeloma (MM) - Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease
Published: January 21, 2015 Content info: 82 Pages

While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor's sub classification. Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival. However, eventually all pts relapse and use of modern diagnosis will enable risk stratification to help distinguish pts along the spectrum of the condition. This can aid in the selection of new treatment options for Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need - POMALYST/ IMNOVID (pomalidomide - POM, Celgene, approved) and Kyprolis (carfilzomib-CFZ, Amgen/ Ono Pharma - JP, approved). While novel targets address unmet need, the pertinent Question remains - is there a need for further improvement? What should be the diagnosis criteria and/or novel imaging / diagnostic tools that can further stratify a pts' risk profile?

Precision medicine approaches in myeloma require fast, robust, and practicable molecular diagnostic tools, and the current diagnostic standard iFISH (interphase fluorescence in situ hybridization) is unable to fulfill any of these criteria. Integration of Diagnostics into therapeutic products/ industry has potential to improve trial design, enhance safety profile, enhance therapeutic efficacy, accelerate trial outcome, and increase commercial success. However, there are few hurdles which are also associated with new model, such as understanding the diagnostic industry, complex trial execution, seeking a 'right' diagnostic partner, managing the co-development process, regulatory uncertainty around companion diagnostics and intellectual property issues.

In this report, we highlight the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM. This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted. The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share. On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ.

Keywords: : Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma, RRMM, Newly Diagnosed Multiple Myeloma, NDMM, molecular diagnostics, FISH, next generation sequencing, Kyprolis, carfilzomib, POMALYST, pomalidomide, Velcade, bortezomib, Revlimid, lenalidomide, Panobinostat, Elotuzumab, Masivet, masitinib, Ixazomib, Aplidin, plitidepsin, Daratumumab, Imbruvica, ibrutinib, Imetelstat, Sylvant, siltuximab, ACE-011, sotatercept, Oprozomib, ARRY-520, filanesib, ALT-801, AT7519M, BT-062, Cabozantinib, Melflufen, KPT-330, selinexor, CT-011, pidilizumab, LymphoSIGHT, microRNAs, ExiLENTSYBR, CLIA-certified, Flow Cytometry, Immunohistochemistry, Illumina, DNA-based cancer diagnostics, Gene Expression Profiling, GEP, iPLEX Genotyping, MMprofiler, GeneChip

Table of Contents
Product Code: 4472

Table of Contents

1. Executive Summary

2. Disease Overview, Diagnosis, and Current Treatment

  • 2.1 Overview of Diagnostic tools for Multiple Myeloma
  • 2.2 Diagnostic Criteria of Myeloma and Recent Amendment
  • 2.3 Diagnostic Approaches for Multiple Myeloma
  • 2.4 Molecular pathogenesis of Myeloma
  • 2.5 Unmet Need
  • 2.6 New Diagnostics Perspective and Technologies
  • 2.7 'Companion' Diagnostics (CDx)
  • 2.8 Genome-wide array
  • 2.9 RNA based technologies
  • 2.10 Next-Generation Sequencing (NGS) technology

3. Diagnostic Tools for Multiple Myeloma

  • 3.1 Affymetrix GeneChip
  • 3.2 SkylineDx MMprofiler
  • 3.3 AgenaBio iPLEX Genotyping
  • 3.4 Signal Genetics MyPRS
  • 3.5 Cancer Genetics Genomic Products
  • 3.6 Illumina NGS
  • 3.7 NeoGenomics CLIA-certified Cancer Test
  • 3.8 Exiqon microRNA PCR
  • 3.9 Regulus Therapeutics microRNA Marker
  • 3.10 Rosetta Genomics Cancer Origin Test
  • 3.11 Sequenta LymphoSIGHT Platform

4. M&A Deals and Market Opportunity in Diagnostic Space

5. Current Therapies

  • 5.1 Newly Diagnosed Multiple Myeloma (NDMM)
    • a. Competitive Landscape for NDMM
  • 5.2 Relapsed and/or Refractory Multiple Myeloma (RRMM)
    • a. Competitive Landscape for RRMM
  • 5.3 Approved Therapies
    • a. Revlimid
    • b. Velcade
    • c. Kyprolis
    • d. POMALYST
  • 5.4 Data Comparison
    • a. Newly Diagnosed Multiple Myeloma (NDMM)
    • b. Relapsed and/or Refractory Multiple Myeloma (RRMM)

6. Novel Targets

  • 6.1 Monoclonal Antibodies
    • a. Elotuzumab
    • b. Situximab
    • c. Daratumumab
    • d. MOR202
    • e. SAR650984
    • f. BI-505
    • g. BHQ880
    • h. CT-011
    • i. IPH2101/ Lirilumab
    • j. BMS-936564 (ulocuplumab)
  • 6.2 Small Molecules
    • a. Panobinostat
    • b. Ixazomib (MLN9708)
    • c. Aplidin (plitidepsin)
    • d. ARRY-520 (filanesib)
    • e. Oprozomib
    • f. KPT-330 (selinexor)
    • g. SNS01-T
    • h. Ibrutinib
    • i. Ricolinostat
    • j. Afuresertib
    • k. KW-2478
    • l. BT-062

7. Clinical Milestones

8. Launch Timeline and Commercial Opportunity of Late-Stage Pipeline

9. M&A/ Licensing Deals and Unpartnered Product Opportunities

Companies mentioned:

  • Affymetrix
  • SkylineDx
  • AgenaBio
  • Signal Genetics
  • Cancer Genetics Inc
  • Illumina
  • NeoGenomics
  • Exiqon
  • Regulus Therapeutics
  • Rosetta Genomics
  • Sequenta
  • Takeda Pharma
  • Celgene
  • Amgen
  • Ono Pharma
  • Abbott
  • BMS
  • Mundipharma
  • Novartis
  • MorphoSys
  • JNJ
  • Innate Pharma
  • Merck
  • Xencor
  • Array Biopharma
  • Altor Bioscience
  • Astex pharma (now Otsuka pharma)
  • Biotest pharma
  • Immunogen
  • Exelixis
  • Oncopeptides
  • Karyopharm Therapeutics
  • CureTech
  • Curis
  • GSK
  • Innate Pharma
  • Lilly
  • Pharmacyclics
Back to Top